Literature DB >> 10361132

The human (PsiL+mu-) proB complex: cell surface expression and biochemical structure of a putative transducing receptor.

B Lemmers1, L Gauthier, V Guelpa-Fonlupt, M Fougereau, C Schiff.   

Abstract

The surrogate light chain (PsiL) associates with mu and Igalpha-Igbeta chains to form the preB-cell receptor that plays a critical role in early B-cell differentiation. Discrepancies exist in human concerning the existence of PsiL+mu- proB cells and the biochemical structure of such a proB-cell complex remains elusive. Among new antihuman VpreB monoclonal antibodies (MoAbs), 5 of the gamma kappa isotype bound to recombinant and native VpreB protein with high affinity. They recognized 4 discrete epitopes, upon which 2 were in the extra-loop fragment. Such MoAbs detected the PsiL at the cell surface of either preB or on both proB and preB cells. The previously reported SLC1/SLC2 MoAbs recognize a conformational epitope specific for the mu/PsiL association in accordance with their preB-cell reactivity. Using the proB/preB 4G7 MoAb, PsiL cell surface expression was detected on normal bone marrow, not only on CD34(-)CD19(+) preB but also on CD34(+)CD19(+) proB cells. Futhermore, this MoAb identified PsiL+mu- fresh proB leukemic cells of the TEL/AML1 type. Biochemical studies showed that, at the proB stage, the PsiL is associated noncovalently with two proteins of 105 and 130 kD. Triggering of this complex induces intracellular Ca2+ flux, suggesting that the PsiL may be involved in a new receptor at this early step of the B-cell differentiation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10361132

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  A new Groucho TLE4 protein may regulate the repressive activity of Pax5 in human B lymphocytes.

Authors:  Michèle Milili; Laurent Gauthier; Julie Veran; Marie-Geneviève Mattei; Claudine Schiff
Journal:  Immunology       Date:  2002-08       Impact factor: 7.397

2.  Complete arrest from pro- to pre-B cells in a case of B cell-negative severe combined immunodeficiency (SCID) without recombinase activating gene (RAG) mutations.

Authors:  K Agematsu; H Nagumo; S Hokibara; T Mori; T Wada; A Yachie; H Kanegane; T Miyawaki; K Sugita; H Karasuyama; A Komiyama
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

3.  The human fetal lymphocyte lineage: identification by CD27 and LIN28B expression in B cell progenitors.

Authors:  Laurie McWilliams; Kuei-Ying Su; Xiaoe Liang; Dongmei Liao; Serina Floyd; Joshua Amos; M Anthony Moody; Garnett Kelsoe; Masayuki Kuraoka
Journal:  J Leukoc Biol       Date:  2013-07-30       Impact factor: 4.962

4.  Stromal cell-derived factor 1 (SDF-1) and antenatal human B cell lymphopoiesis: expression of SDF-1 by mesothelial cells and biliary ductal plate epithelial cells.

Authors:  A Coulomb-L'Hermin; A Amara; C Schiff; I Durand-Gasselin; A Foussat; T Delaunay; G Chaouat; F Capron; N Ledee; P Galanaud; F Arenzana-Seisdedos; D Emilie
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

5.  Modeling first-hit functions of the t(12;21) TEL-AML1 translocation in mice.

Authors:  Shinobu Tsuzuki; Masao Seto; Mel Greaves; Tariq Enver
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-20       Impact factor: 11.205

6.  Galectin-1 is a stromal cell ligand of the pre-B cell receptor (BCR) implicated in synapse formation between pre-B and stromal cells and in pre-BCR triggering.

Authors:  Laurent Gauthier; Benjamin Rossi; Florence Roux; Elise Termine; Claudine Schiff
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-23       Impact factor: 11.205

7.  Activated interleukin-7 receptor signaling drives B-cell acute lymphoblastic leukemia in mice.

Authors:  Kerri R Thomas; Eric J Allenspach; Nathan D Camp; Michelle N Wray-Dutra; Socheath Khim; Anna Zielinska-Kwiatkowska; Andrew E Timms; Joseph P Loftus; H Denny Liggitt; Katia Georgopoulos; Sarah K Tasian; Richard G James; David J Rawlings
Journal:  Leukemia       Date:  2021-06-30       Impact factor: 11.528

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.